IGF-1LR3

XENE BIOLABS RESEARCH SERIES
FOR RESEARCH USE ONLY

Category: Lipolytic Peptide | Half-life: 20-30 min

Mechanism

Modified hGH Frag 176-191 | FRAG-X. Tyr-hGH 177-191. Same fat-burning domain as Frag, stabilized. No GH/IGF-1 effects.

Dosing Protocol

Reconstitution: 2 mg + 1 mL BAC = 2 mg/mL. 300 mcg = 0.15 mL = 15 units.

Critical: Identical to hGH Frag 176-191 | FRAG-X. Must be fasted. Insulin blocks effect.

IGF-1LR3 | Long-Acting IGF-1 Analogue — Systemic Anabolic | CAS: 143045-27-6

IGF-1 LR3 is a synthetic analogue of IGF-1 with an arginine substitution at position 3 and a 13 amino acid N-terminal
extension. These modifications reduce IGFBP binding by ~1000x and extend half-life to 20–30 hours, enabling systemic
anabolic activity. Promotes nitrogen retention, muscle protein synthesis, anti-catabolism, and satellite cell activation.

DOSING PROTOCOL
ParameterDetails
Dose20–60 mcg/day SubQ or IM
TimingPost-workout or AM fasted
Cycle Length4 weeks on; 4–6 weeks off (GH axis feedback)
STACKING RECOMMENDATIONS

Pair with PEG-MGF for local + systemic IGF coverage. GH secretagogues provide upstream GH pulse to support IGF-1
LR3 activity. TRT base essential. BPC-157 for joint/tendon support under loading

NOTE: Monitor fasting glucose — systemic IGF-1 has significant insulin-mimetic effects. Can cause hypoglycemia. Cycle strictly to avoid
IGF-1 feedback suppression.